- Home
- CRMD vs DCTH Comparison
CRMD vs DCTH Comparison
Compare CRMD & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRMD | DCTH |
|---|---|---|
| Founded | 2006 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 590.7M | 578.4M |
| IPO Year | 2009 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CRMD | DCTH |
|---|---|---|
| Price | $8.09 | $16.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $14.83 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 1.3M | 665.3K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 780.00 | 107.53 |
| EPS | ★ 0.72 | 0.04 |
| Revenue | ★ $311,709,000.00 | N/A |
| Revenue This Year | $0.30 | $24.54 |
| Revenue Next Year | N/A | $33.15 |
| P/E Ratio | ★ $10.65 | $426.25 |
| Revenue Growth | ★ 617.03 | N/A |
| 52 Week Low | $6.13 | $8.12 |
| 52 Week High | $14.96 | $17.42 |
Technical Indicators
Market Signals| Indicator | CRMD | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 55.36 | 68.81 |
| Support Level | $8.09 | $10.16 |
| Resistance Level | $8.92 | $17.42 |
| Average True Range (ATR) | 0.39 | 0.82 |
| MACD | 0.08 | 0.32 |
| Stochastic Oscillator | 54.79 | 89.81 |
Price Performance
Historical ComparisonAbout CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.